Exenatide
Myocardial Infarction
Saint Luke's Health Systemprotein_peptidePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Myocardial Infarction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aspirin Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | A |
CLOPIDOGREL Shanghai CureGene Pharmaceutical Co., Ltd. | Phase 4 | A |
Ticagrelor Assistance Publique - Hôpitaux de Paris | Phase 4 | BBB |
PYRIDOXOL Hamilton Health Sciences Corporation | Phase 4 | BBB |
Folic Acid Hamilton Health Sciences Corporation | Phase 4 | BBB |
View all 37 →
Same molecule, other indications
Exenatide is also rated in:
metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative · Phase 4
74 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →